NY-IFF
29.2.2024 22:16:30 CET | Business Wire | Press release
IFF (NYSE: IFF)—a world leader in food and beverage, home and personal care, and health—has been named the top American Company for gender equality and tenth globally by Equileap, a leading organization providing data and insights on gender equality in the corporate sector.
In its seventh annual Gender Equality Global Report & Ranking, Equileap provides a status update on gender equality in the corporate world, evaluating 19 different criteria that range from the gender pay gap and female representation at all corporate levels to parental leave and anti-sexual harassment policies. The research examined 3,795 companies, representing 103 million employees globally, that are listed on a major index or in one of 27 developed markets.
“We’re very proud of this recognition by Equileap—the largest provider of gender data to the investor community—which highlights the progress we’ve made and the deliberate actions we’ve taken to achieve gender equality for IFFers,” said Deb Borg, IFF chief human resources, diversity & inclusion, and communications officer. “This progress belongs to all of us who have imagined a more inclusive future and acted on that inspiration. We believe that embracing the uniqueness of our diverse workforce unleashes innovative possibilities at the intersection of science and creativity.”
“By intentionally considering inclusion in how we make decisions, build programs, implement our talent processes and create policies, we ask ourselves how we are eliminating barriers to access so that fair outcomes can flourish at IFF,” said Erik Fyrwald, IFF CEO. “We know that a more diverse and inclusive IFF benefits our people, customers, industry, and communities.”
IFF’s recognition as the leader in Gender Equality highlights the following progress in 2023:
- Continued progress against its ESG aspiration of achieving Gender Parity at all levels, reaching 40% of the Executive Leadership Team and 38% of senior leadership in 2023
- Continued to analyze pay equity; data shows the Company has no statistically significant gender pay gaps.
- Committed to the Living Wage Pledge and embarked on the journey to ensure all our employees around the world receive a living wage as defined within their country.
- Continued to pursue equitable representation in Leadership Development programs.
- Piloted Ignite your Impact, a program designed to help women navigate some of the unique challenges they face in leadership.
- Launched Mentor@IFF, IFF’s enterprise-wide mentoring program.
- Launched products through IFF Health that are helping women navigate the symptoms of menopause.
- Increased spending with women suppliers by 13% in our Supplier Diversity efforts.
-
Supported women in the communities in which we work:
- In the LMR Serbian platform, IFF supported women's entrepreneurship, providing access to alternative income streams by empowering women to manage their own beehives and make honey to sell to local markets.
- In the guar program in India, objectives included improving knowledge and support devices for women's empowerment. The project started in 2021, and since then, IFF has provided training to 230+ farmers and community members on the topic of women’s empowerment, highlighting the importance of women’s role in the field. IFF also provided 200 women farmers with farming tools to aid their work.
“While we are proud of this recognition and our progress, we recognize there’s much more to do,” said Borg. “In 2024, we will continue our partnership with EDGE—which has been instrumental in our efforts over the years—to advance equity at IFF. We will undergo EDGE Certification in all countries with 200 or more employees.”
To learn more about IFF’s leading Diversity, Equity and Inclusion efforts, visit here.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
© 2024 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229914819/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
